Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaAlireza Eghtedar, Hagop Kantarjian, Elias Jabbour, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Oncotargets and Therapy|December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomesSrdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.
Leukemia & Lymphoma|August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceOhad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
Blood|January 10, 2012
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Cancer Cell|September 29, 2015
hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic MalignanciesMiguel Gallardo, Hun Ju Lee, Xiaorui Zhang, et al.
Pageof 4